Market Snapshot

2018 - 2026
2020
North America
North America
>6.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The diabetes care devices market is expected to register a CAGR greater than 6.8% during the forecast period (2020-2025). North America is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the region. There has been a significant rise in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose levels is the continuous glucose monitoring devices.
Scope of the Report
The study provides a detailed analysis of the diabetes care devices market, globally, and it includes market share and size, forecast, and industry overview. The report also offers a country-wise analysis.
Monitoring Devices (Value and Volume, 2012-2025) | |||||
| |||||
|
Management Devices (Value and Volume, 2012-2025) | |||||
| |||||
Insulin Syringes | |||||
Insulin Cartridges | |||||
Disposable Pens | |||||
Jet Injectors |
Geography | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
|
Key Market Trends
Rising Prevalence of Diabetes
The diabetes care devices market reached USD 69.7 billion in 2019, and it is anticipated to register a CAGR of 4.6% during the forecast period (2020-2025). Approximately 4.2 million adults aged 20-79 years were estimated to die as a result of diabetes and its complications in 2019. This is equivalent to one death every eight seconds. Diabetes is estimated to be associated with 11.3% of global deaths from all causes among people in this age group. Almost half (46.2%) of the deaths associated with diabetes among the age group of 20-79 years are of people under the age of 60 years, i.e., the working-age group. Globally, there are more deaths associated with diabetes in women (2.3 million) than in men (1.9 million).

To understand key trends, Download Sample Report
North America to Dominate the Monitoring Devices Segment
The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles. Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, a growing obese population, and government initiatives of raising awareness regarding diabetic care. According to IDF, in 2019, USD 324.5 billion was spent on diabetes in the region, which is 42.7% of the total global health expenditure on diabetes. In North America, USD 294.6 billion was spent in the United States alone. The mean annual expenditure per person with diabetes was highest in the United States (USD 9,506), followed by Canada (USD 4,397).

To understand geography trends, Download Sample Report
Competitive Landscape
There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of a few strategic outcomes include:
- In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for its Guardian (TM) Connect Continuous Glucose Monitoring (CGM) system, for people with diabetes aged between 14 and 75 years.
- In October 2019, the US Food and Drug Administration (FDA) cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use on patients aged between two years and above.
Major Players

Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Bargaining Power of Suppliers
-
4.4.2 Bargaining Power of Consumers
-
4.4.3 Threat of New Entrants
-
4.4.4 Threat of Substitute Products and Services
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. Market Segmentation
-
5.1 Monitoring Devices (Value and Volume, 2012-2025)
-
5.1.1 Self-monitoring Blood Glucose Devices
-
5.1.1.1 Glucometer Devices
-
5.1.1.2 Test Strips
-
5.1.1.3 Lancets
-
-
5.1.2 Continuous Glucose Monitoring
-
5.1.2.1 Sensors
-
5.1.2.2 Durables
-
-
-
5.2 Management Devices (Value and Volume, 2012-2025)
-
5.2.1 Insulin Pumps
-
5.2.1.1 Insulin Pump Device
-
5.2.1.2 Insulin Pump Reservoir
-
5.2.1.3 Infusion Set
-
-
5.2.2 Insulin Syringes
-
5.2.3 Insulin Cartridges
-
5.2.4 Disposable Pens
-
5.2.5 Jet Injectors
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States (Value and Volume, 2012 - 2025)
-
5.3.1.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.1.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.1.2 Canada (Value and Volume, 2012 - 2025)
-
5.3.1.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.1.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.1.3 Rest of North America (Value and Volume, 2012 - 2025)
-
5.3.1.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.1.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
-
5.3.2 Europe
-
5.3.2.1 France (Value and Volume, 2012 - 2025)
-
5.3.2.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.2.2 Germany (Value and Volume, 2012 - 2025)
-
5.3.2.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.2.3 Italy (Value and Volume, 2012 - 2025)
-
5.3.2.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.2.4 Spain (Value and Volume, 2012 - 2025)
-
5.3.2.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.2.5 United Kingdom (Value and Volume, 2012 - 2025)
-
5.3.2.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.2.6 Russia (Value and Volume, 2012 - 2025)
-
5.3.2.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2025)
-
5.3.2.7.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.2.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
-
5.3.3 Latin America
-
5.3.3.1 Mexico (Value and Volume, 2012 - 2025)
-
5.3.3.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.3.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.3.2 Brazil (Value and Volume, 2012 - 2025)
-
5.3.3.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.3.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2025)
-
5.3.3.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.3.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
-
5.3.4 Asia-Pacific
-
5.3.4.1 Japan (Value and Volume, 2012 - 2025)
-
5.3.4.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.2 South Korea (Value and Volume, 2012 - 2025)
-
5.3.4.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.3 China (Value and Volume, 2012 - 2025)
-
5.3.4.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.4 India (Value and Volume, 2012 - 2025)
-
5.3.4.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.5 Australia (Value and Volume, 2012 - 2025)
-
5.3.4.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.6 Vietnam (Value and Volume, 2012 - 2025)
-
5.3.4.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.7 Malaysia (Value and Volume, 2012 - 2025)
-
5.3.4.7.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.8 Indonesia (Value and Volume, 2012 - 2025)
-
5.3.4.8.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.8.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.9 Philippines (Value and Volume, 2012 - 2025)
-
5.3.4.9.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.9.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.10 Thailand (Value and Volume, 2012 - 2025)
-
5.3.4.10.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.10.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2025)
-
5.3.4.11.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.4.11.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
-
5.3.5 Middle-East and Africa
-
5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2025)
-
5.3.5.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.5.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.5.2 Iran (Value and Volume, 2012 - 2025)
-
5.3.5.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.5.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.5.3 Egypt (Value and Volume, 2012 - 2025)
-
5.3.5.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.5.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.5.4 Oman (Value and Volume, 2012 - 2025)
-
5.3.5.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.5.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.5.5 South Africa (Value and Volume, 2012 - 2025)
-
5.3.5.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.5.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
5.3.5.6 Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)
-
5.3.5.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
-
5.3.5.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
-
-
-
-
-
6. MARKET INDICATORS
-
6.1 Type-1 Diabetes Population (2012-2025)
-
6.2 Type-2 Diabetes Population (2012-2025)
-
-
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
-
7.1.1 Abbott
-
7.1.2 F. Hoffmann-La Roche AG
-
7.1.3 Johnson & Johnson
-
7.1.4 Dexcom
-
7.1.5 Medtronic
-
7.1.6 Novo Nordisk
-
7.1.7 Ascensia Diabetes Care
-
7.1.8 AgaMatrix
-
7.1.9 Bionime Corporation
-
7.1.10 Omnipod
-
7.1.11 Medisana
-
7.1.12 Trivida
-
7.1.13 Rossmax International Ltd
-
-
-
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Diabetes Care Devices Market market is studied from 2018 - 2026.
What is the growth rate of Diabetes Care Devices Market?
The Diabetes Care Devices Market is growing at a CAGR of >6.8% over the next 5 years.
Which region has highest growth rate in Diabetes Care Devices Market?
North America is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Diabetes Care Devices Market?
North America holds highest share in 2020.
Who are the key players in Diabetes Care Devices Market?
- Dexcom
- Medtronic
- F. Hoffmann-La Roche AG
- Novo Nordisk
- Omnipod
Are the major companies operating in Diabetes Care Devices Market.